Pavel Raifeld, Chief Executive Officer of Innoviva, Inc., stated: “ RELVAR ® /BREO ® ELLIPTA ® global net sales increased by 5%, ANORO ® ELLIPTA ® global net sales increased by 10%, and TRELEGY ® ...

DUBLIN, June 2, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") today announced that it has entered into a definitive agreement to sell its remaining royalty ...

The FDA’s acceptance for filing of our ANDA for fluticasone furoate, umeclidinium, and vilanterol inhalation powder, a generic version of Trelegy® Ellipta®, is another major milestone in advancing our ...

Theravance Biopharma TBPH announced that it has entered into an agreement to sell its remaining royalty interest in net sales of Trelegy Ellipta to GSK plc GSK for $225 million in cash. Theravance ...

Medicare Part D prescription drug plans may cover Trelegy Ellipta inhalers. Out-of-pocket costs can vary by plan and insurer, but you may only have to pay a 25% ...

Theravance Biopharma TBPH recently announced that it has entered into a definitive agreement with Royalty Pharma RPRX to sell all of the former’s equity interests in Theravance Respiratory Company LLC ...

China NMPA approves GSK’s Trelegy Ellipta for use in adults with uncontrolled asthma: London, UK Saturday, January 24, 2026, 09:00 Hrs [IST] GSK plc announced that China’s Nat ...

Federal antitrust officials have redoubled efforts to challenge what they see as improper pharma patent listings that delay the market entry of generic drugs. This week, the Federal Trade Commission ...

If a person has a Medicare Part D prescription drug plan, it may cover the costs of Trelegy Ellipta inhalers. Although out-of-pocket costs can vary by plan ...